Biological and pathological functions of novel types of secretory phospholipase A2s and their receptors

Annual Report of Shionogi Research Laboratory

Volumn , Issue 52, 2002, Pages 1-22

  Hanasaki, Kohji ^a   Arita, Hitoshi ^a  

^a SHIONOGI AND CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; CALCIMYCIN; COMPLEMENTARY DNA; COPPER ION; CYCLOOXYGENASE 2 INHIBITOR; CYTOKINE; GLYCEROPHOSPHOLIPID; INDOMETACIN; INDOXAM; LIGAND; LOW DENSITY LIPOPROTEIN; MEMBRANE RECEPTOR; MESSENGER RNA; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHOLIPASE A2; PHOSPHOLIPASE A2 INHIBITOR; PROSTAGLANDIN E2; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ATHEROSCLEROSIS; CANCER CELL; CELL ACTIVATION; COLON CANCER; CONTROLLED STUDY; ENDOCYTOSIS; ENZYME ACTIVITY; ENZYME REGULATION; ENZYME SPECIFICITY; ENZYME STRUCTURE; ENZYME SUBSTRATE; FOAM CELL; HUMAN; HYDROLYSIS; INFLAMMATION; MACROPHAGE FUNCTION; NONHUMAN; REVIEW;

EID: 0036420575     PISSN: 05598680     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (86)

1. 2 in the pathobiology of disease. Lab. Invest., 55, 391-404 (1986).
2. 2: Its generation and role in platelet activation. Prog. Lipid Res., 28, 273-301 (1989).
3. 2 enzymes: Classification and characterization. Biochim. Biophys. Acta, 1488, 1-19 (2000).
4. 2 and their receptors and binding proteins. Biochim. Biophys. Acta, 1488, 59-70 (2000).
5. 2 receptor. Arch. Biochem. Biophys., 372, 215-223 (1999).
6. de Haas, G. H., Postema, N. M., Nieuwenhuizen, W. and van Deenen, L. L. M., Purification and properties of an anionic zymogen of phospholipase A from porcine pancreas. Biochim. Biophys. Acta, 159, 118-129 (1968).
7. 2 into receptor binding, active forms. Biochem. Biophys. Res. Commun., 198, 10-15 (1994).
8. 2 mRNA in rat gastric mucosa and lung. Biochim. Biophys. Acta, 1007, 124-126 (1989).
9. 2 in Swiss 3T3 cells via specific binding site. J. Biol. Chem., 266, 19139-19141 (1991).
10. 2 mRNA synthesis is stimulated by two distinct mechanisms in rat vascular smooth muscle cells. FEBS Lett., 261, 171-174 (1990).
11. 2 in oleic acid-induced acute lung injury in rabbits. Am. J. Respir. Crit. Care Med., 160, 1292-1302 (1999).
12. 2 as a therapeutic target. Biochim. Biophys. Acta, 1488, 182-187 (2000).
13. 2: Synthesis and inhibitory activities of indolizine and indene derivatives. J. Med. Chem., 39, 3636-3658 (1996).
14. 2 S-1. J. Biol. Chem., 263, 5732-5738 (1988).
15. 2 induced prominent release of arachidonic acid from human myeloid leukemia cells. J. Biol. Chem., 274, 34203-34211 (1999).
16. 2 gene in inbred mouse strains. J. Biol. Chem., 270, 22378-22385 (1995).
17. Wooley, P. H., Luthra, H. S., Griffiths, M. M., Stuart, J. M., Huse, A. and David, C. S., Type II collagen-induced arthritis in mice. IV. Variations in immunogenetic regulation provide evidence for multiple arthritogenic epitopes on the collagen molecule. J. Immunol., 135, 2443-2451 (1985).
18. 2-independent mechanisms. Biochim. Biophys. Acta, 1438, 213-222 (1999).
19. 2 gene family in mammals. J. Biol. Chem., 272, 17247-17250 (1997).
20. 2. J. Biol. Chem., 269, 2365-2368 (1994).
21. 2. J. Biol. Chem., 272, 15745-15752 (1997).
22. 2s. J. Biol. Chem., 274, 24973-24979 (1999).
23. 2s. J. Biol. Chem., 275, 5785-5793 (2000).
24. 2. J. Biol. Chem., 274, 31195-31202 (1999).
25. 2 with homology to the group III bee venom enzyme. J. Biol. Chem., 275, 7492-7496 (2000).
26. 2. J. Biol. Chem., 275, 39823-39826 (2000).
27. 2 receptor. Arch. Biochem. Biophys., 381, 31-42 (2000).
28. Halban, P. A. and Irminger, J. C., Sorting and processing of secretory proteins. Biochem. J., 299, 1-18 (1994).
29. 2. Biochim. Biophys. Acta, 1394, 57-64 (1998).
30. 2 that mediates prostaglandin production in mast cells. J. Biol. Chem., 272, 13591-13596 (1997).
31. 2 induces potent productions of various lipid mediators in mouse peritoneal macrophages. Biochim. Biophys. Acta, 1530, 67-76 (2001).
32. 2s in regulating arachidonic acid release and prostaglandin generation. Implications of cyclooxygenase-2 induction and phospholipid scramblase-mediated cellular membrane perturbation. J. Biol. Chem., 274, 31435-31444 (1999).
33. van Deventer, S. J., Buller, H. R., ten Cate, J. W., Aarden, L. A., Hack, C. E. and Sturk, A., Experimental endotoxemia in humans: Analysis of cytokine release and coagulation, fibrinolytic, and complement pathways. Blood, 76, 2520-2526 (1990).
34. Quinn, M. T., Parthasarathy, and Steinberg, S. D., Lysophosphatidylcholine: A chemotactic factor for human monocytes and its potential role in atherogenesis. Proc. Natl., Acad. Sci. USA, 85, 2805-2809 (1988).
35. Marnett, L. J., Aspirin and related nonsteroidal anti-inflammatory drugs as chemopreventive agents against colon cancer. Prev. Med., 24, 103-106 (1995).
36. Sano, H., Kawahito, Y., Wilder, R. L., Hashiramoto, A., Mukai, S., Asai, K., Kimura, S., Kato, H., Kondo, M. and Hla, T., Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res., 55, 3785-3789 (1995).
37. Oshima, M., Dinchuk, J. E., Kargman, S. L., Oshima, H., Hancock, B., Kwong, E., Trzaskos, J. M., Evans, J. F. and Taketo, M. M., Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell, 87, 803-809 (1996).
38. Rigas, B., Goldman, I.S. and Levine, L., Altered eicosanoid levels in human colon cancer. J. Lab. Clin. Med., 122, 518-523 (1993).
39. Masferrer, J. L., Leahy, K. M., Koki, A. T., Zweifel, B. S., Settle, S. L., Woerner, B. M., Edwards, D. A., Flickinger, A. G., Moore, R. J. and Seibert, K., Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res., 60, 1306-1311 (2000).
40. Watanabe, K., Kawamori, T., Nakatsugi, S., Ohta, T., Ohuchida, S., Yamamoto, H., Maruyama, T., Kondo, K., Ushikubi, F., Narumiya, S., Sugimura, T. and Wakabayashi, K., Role of the prostaglandin E receptor subtype EP1 in colon carcinogenesis. Cancer Res., 59, 5093-5096 (1999).
41. 2 in Apc (Delta 716) knockout mice. Nat. Med., 7, 1048-1051 (2001).
42. 2 formation during colon tumorigenesis. FEBS Lett., 487, 262-266 (2000).
43. Glass, C. K. and Witztum, J. L., Atherosclerosis. the road ahead. Cell, 104, 503-516 (2001).
44. Napoli, C., D'Armiento, F. P., Mancini, F. P., Postiglione, A., Witztum, J. L., Palumbo, G. and Palinski, W., Fatty streak formation occurs in human fetal aortas and is greatly enhanced by maternal hypercholesterolemia. Intimal accumulation of low density lipoprotein and its oxidation precede monocyte recruitment into early atherosclerotic lesions. J. Clin. Invest., 100, 2680-2690 (1997).
45. Yusuf, S., Dagenais, G., Pogue, J., Bosch, J. and Sleight, P., Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med., 342, 154-160 (2000).
46. 2 induces particle aggregation in the absence and fusion in the presence of heparin. Arterioscler. Thromb. Vasc. Biol., 19, 1276-1283 (1999).
47. 2 and decorin in human atherosclerotic lesions. Circ. Res., 86, 707-714 (2000).
48. 2 induces particle fusion and enhances the retention of LDL to human aortic proteoglycans. Arterioscler. Thromb. Vasc. Biol., 21, 1053-1058 (2001).
49. 2 is linked to macrophage form cell formation. J. Biol. Chem., 277, 29116-19124 (2002).
50. Jerome, W. G. and Lewis, J. C., Early atherogenesis in White Carneau pigeons. II. Ultrastructural and cytochemical observations. Am. J. Pathol., 119, 210-222 (1985).
51. 2 in the metabolism of lipoproteins. Substrate specificities of the enzymes and the regulation of their activities by sphingomyelin. Biochemistry, 41, 4911-4920 (2002).
52. 2 involved in arachidonic acid mobilization in murine P388D1 macrophages. J. Biol. Chem., 271, 32381-32384 (1996).
53. 2 receptor. Prog. Lipid Res., 34, 117-138 (1995).
54. 2 in the rat. Its cellular and tissue distribution. J. Biol. Chem., 267, 6414-6420 (1992).
55. 2. Biochim. Biophys. Acta, 1127, 233-241 (1992).
56. 2 receptor. J. Biol. Chem., 269, 5897-5904 (1994).
57. 2. J. Biol. Chem., 269, 1575-1578 (1994).
58. 2. Trends Pharmacol. Sci., 20, 162-170 (1999).
59. 2. Molecular cloning, identification of a secreted soluble form, expression, and chromosomal localization. J. Biol. Chem., 270, 8963-8970 (1995).
60. 2 receptors from various mammals. Eur. J. Biochem., 225, 375-382 (1994).
61. 2 to its specific receptor. Biochem. Biophys. Res. Commun., 209, 293-299 (1995).
62. 2 via its high affinity receptor stimulates extracellular matrix invasion by normal and cancer cells. J. Biol. Chem., 272, 2346-2353 (1997).
63. 2 receptor during murine endotoxic shock. Arch. Biochem. Biophys., 379, 7-17 (2000).
64. 2 are natural ligands of the mouse 180-kDa M-type receptor. J. Biol. Chem., 274, 7043-7051 (1999).
65. 2 production in rat mesangial cells by receptor binding reaction. J. Biochem., 117, 420-424 (1995).
66. 2 is separable from its enzymatic activity. FEBS Lett., 324, 349-352 (1993).
67. 2. J. Biol. Chem., 274, 19152-19160 (1999).
68. 2 receptor. FEBS Lett., 478, 187-191 (2000).
69. 2 in a human pancreatic cancer cell line. FEBS Lett., 407, 343-346 (1997).
70. Cocks, T. M. and Moffatt, J. D., Protease-activated receptors: sentries for inflammation? Trends Pharmacol. Sci., 21, 103-108 (2000).
71. 2 via specific binding sites. Biochim. Biophys. Acta, 1125, 210-214 (1992).
72. 2 in rat ovaries: Stimulatory action on progesterone release. Endocrinology, 135, 603-609 (1994).
73. 2 via its specific binding site. FEBS Lett., 303, 217-220 (1992).
74. 2. Biochim. Biophys. Acta, 1393, 253-266 (1998).
75. 2 in murine bone marrow-derived mast cells. J. Immunol., 165, 2773-2782 (2000).
76. 1) via a specific binding site. J. Biol. Chem., 268, 2865-2871 (1993).
77. 2 expression and prostaglandin biosynthesis in rat mesangial cells. J. Biol. Chem., 269, 5092-5098 (1994).
78. 2 receptor-deficient mice. J. Biol. Chem., 272, 32792-32797 (1997).
79. 2 propeptide in acute lung injury. Lancet, 344, 1472-1473 (1994).
80. 2 receptor. FEBS Lett., 509, 250-254 (2001).
81. 2-I in proliferative cells. J. Cell Sci., 111, 985-994 (1998).
82. 2. J. Biol. Chem., 277, 13583-13588 (2002).
83. 2 and beta-neurotoxicity. Biochimie, 82, 807-814 (2000).
84. 2 with neurotoxic activity is a calmodulin. J. Biol. Chem., 276, 12493-12496 (2001).
85. 2? Biochimie, 82, 815-831 (2000).
86. 2. Eur. J. Biochem., 267, 4960-4969 (2000).